---
schema_version: "secwatch.filing_event.v1"
accession: "0001021771-24-000190"
form_type: "8-K"
ticker: "BRTX"
cik: "0001505497"
company_name: "BioRestorative Therapies, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:29:48.715858+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# BioRestorative to present Phase 2 BRTX-100 data at spine symposium; Q3 results call Nov 13

## Summary
- Additional preliminary 26-52 week blinded data from Phase 2 trial of BRTX-100 for chronic lumbar disc disease to be presented on Nov 13, 2024.
- Presentation at Orthopaedic Research Society/Philadelphia Spine Research Society 7th International Spine Research Symposium, Nov 10-14.
- Company will host webcasted conference call Nov 13 at 4:30pm ET to review data, Q3 2024 financial results, and provide business update.

## SEC filing metadata
- accession: 0001021771-24-000190
- form_type: 8-K
- ticker: BRTX
- cik: 0001505497
- company_name: BioRestorative Therapies, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1505497/000102177124000190/0001021771-24-000190-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1505497/000102177124000190/brt8k11624.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001021771-24-000190
- JSON: https://secwatch.observer/filing/0001021771-24-000190.json
- Plain text: https://secwatch.observer/filing/0001021771-24-000190.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.